Dr. Reddy's Laboratories Profit Drops In Q2

Dr. Reddy's Laboratories reported a 36% drop in Q2 profit to INR 9,134 million, or INR 11.10 per share, from the prior year. Revenue declined to INR 86,708 million, driven by lower lenalidomide sales in North America. Pre-market trading showed a 0.76% increase to $13.32 on the NYSE.

Original reporting
Published Oct 23, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 1:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$RDY
Bearish
high confidence
Mentioned
$RDY
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$RDYBearishMed
01

Why it matters

The earnings miss may prompt short‑term selling pressure, though longer‑term fundamentals remain to be assessed.

02

Market read

Primary earnings disclosure for a mid‑cap pharma ADR; relevant for traders with exposure to emerging‑market health stocks.

03

What to watch

Currency fluctuations and one‑off product mix effects could mitigate the earnings impact.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Dr. Reddy's Laboratories Limited (RDY) released its Q2 FY2027 earnings, showing a 36% profit decline and modest revenue drop.

Company-level read

Ticker impact

$RDYBearishHigh confidence
Context

Dr. Reddy's reported Q2 profit down 36% YoY, with revenue decline, marking the first public disclosure of these results.

Expected impact

likely downside as investors price in lower profit and revenue.

Evidence & confidence

Profit and revenue both fell year‑over‑year; market already reacted modestly pre‑market, suggesting further pressure.

Market effects

Indian pharma earnings weakness may weigh on sector peers.

Potential drag on Indian‑focused ADRs and related biotech stocks.

Limited to investors tracking emerging‑market pharma.

Counterpoint

If the decline is seen as temporary, the stock could be a buying opportunity at lower levels.

Key entities

  • Dr. Reddy's Laboratories Limited

    Indian pharmaceutical company listed on NYSE as RDY.

Related articles

$RDYHigh

Dr.Reddy's Wins Brazil Approval For Generic Ozempic Alternative

Dr. Reddy's Laboratories (RDY) received approval from Brazil's ANVISA for its generic semaglutide injection, a diabetes treatment similar to Novo Nordisk's Ozempic. The product will be marketed in Brazil, a key market with 16.6 million diabetes patients and a $244.6 million semaglutide market. RDY plans to launch the product via a partnership with Ache. RDY stock closed at $14.77, up 3.29%, and is down 0.10% in pre-market trading.

$RDYMed

Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery

Dr. Reddy's Laboratories reported a 1.5% year-over-year revenue decline, driven by lower lenalidomide sales and declines in North America, Europe, and PSAI businesses. The company expects margins to improve with new products and business mix, targeting a 55% gross margin. Semaglutide relaunch is planned for November 2026, and abatacept biosimilar approval is expected by December 2026.

$RDYHigh

DR REDDYS LABORATORIES LTD (RDY): Financial results for H1 2027

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia